530 related articles for article (PubMed ID: 33141869)
1. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
[TBL] [Abstract][Full Text] [Related]
2. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy.
Roberti R; Iannone LF; Palleria C; De Sarro C; Spagnuolo R; Barbieri MA; Vero A; Manti A; Pisana V; Fries W; Trifirò G; Naturale MD; Larussa T; De Francesco AE; Bosco V; Donato di Paola E; Citraro R; Luzza F; Bennardo L; Rodinò S; Doldo P; Spina E; Russo E; De Sarro G
Curr Med Res Opin; 2020 Sep; 36(9):1457-1463. PubMed ID: 32573307
[TBL] [Abstract][Full Text] [Related]
3. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
[TBL] [Abstract][Full Text] [Related]
4. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
Palleria C; Iannone L; Leporini C; Citraro R; Manti A; Caminiti M; Gigliotti P; Grembiale RD; L'Andolina M; Muccari G; Naturale MD; Olivo D; Pagano Mariano G; Pellegrini R; Varcasia G; Abdalla K; Russo E; Ursini F; De Sarro G
PLoS One; 2018; 13(10):e0205134. PubMed ID: 30356301
[TBL] [Abstract][Full Text] [Related]
5. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
6. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
7. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
8. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
[TBL] [Abstract][Full Text] [Related]
9. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
11. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
12. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
[TBL] [Abstract][Full Text] [Related]
13. Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
Barbieri MA; Cicala G; Cutroneo PM; Gerratana E; Palleria C; De Sarro C; Vero A; Iannone L; Manti A; Russo E; De Sarro G; Atzeni F; Spina E
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32344563
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
15. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
16. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
17. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
van der Schoot LS; van den Reek JMPA; Groenewoud JMM; Otero ME; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Berends MAM; Arnold WP; Peters B; Andriessen MPM; Den Hengst CW; Kuijpers ALA; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1913-1920. PubMed ID: 31177583
[TBL] [Abstract][Full Text] [Related]
18. Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
.
Vergani HM; Calvini G; Mangini G; Mattioli F; Parodi A; Burlando M; Bodini G; Martelli A
Int J Clin Pharmacol Ther; 2020 Apr; 58(4):208-213. PubMed ID: 32053103
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
